Tirzepatide, known by its brand name Mounjaro, is a once-weekly injection that works by targeting two different receptors in the brain: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor (GLP-1)
Then again, I was close to one of them here in Copenhagen, so the work that he did actually inspired me to say I was in a pharma setting where I saw some people were working on type 2 diabetes and as you're saying it could be before insulin, trying to maybe compete with tablets, metformin, and sulfonylureas
Administration: The treatment is expected to be supplied in a pre-filled injection pen, similar to Mounjaro and Wegovy pens
Current guidance suggests using a barrier method, such as condoms, for at least four weeks after starting Mounjaro and for four weeks after each dose increase
The findings of this study do not prove that sweeteners pose any real risk to humans